Rocket Lab's Neutron Delay and Backlog Guidance Highlight Persistent Execution Risks

What happened

Rocket Lab exceeded Q4 and FY25 earnings expectations but delayed the Neutron rocket's first launch to Q4 2026 after a tank rupture during testing, underscoring ongoing development challenges. Management guided that 37% of its $1.85 billion backlog will convert over the next 12 months, a figure some analysts consider conservative, potentially offering revenue upside. However, gross margins are expected to decline due to lower-margin Space Development Agency contracts and the costs of Neutron's production ramp, adding pressure to already loss-making operations. This news aligns with the DeepValue report's view that Rocket Lab's valuation hinges on timely execution of its defense prime narrative and Neutron milestones, amidst a crowded market sentiment. Despite record revenue growth, the company continues to burn cash with negative free cash flow, emphasizing the binary risk-reward profile investors must navigate.

Implication

The Neutron delay reinforces the execution risks highlighted in the DeepValue report, increasing the probability of further capital raises and dilution if timelines slip again. Backlog conversion guidance provides a revenue buffer but may not offset margin compression from SDA contracts, potentially dampening near-term profitability. With the valuation embedding a seamless defense ramp and Neutron success, additional delays could trigger significant downside, as per the report's potential sell rating. Investors should closely monitor quarterly results against guidance and Neutron milestone progress over the next 6-12 months for de-risking signals. Given the high conviction in the report and persistent cash burn, a cautious approach with smaller position sizes is advisable until clear execution improvements emerge.

Thesis delta

The new article confirms the Neutron delay and margin pressures, reinforcing the DeepValue report's thesis that Rocket Lab's valuation demands flawless execution with high downside risk from any slippage. While backlog conversion might exceed guidance, this does not materially alter the core investment thesis, which remains centered on monitoring Neutron milestones and defense contract conversion to avoid dilution and valuation re-rating.